Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPATIA: Hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies
2023-504661-23-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in antiphospholipid syndrome (APS) and Antiphospholipid antibody positivity (aPL) comparing Hydroxychloroquine arm with Placebo arm (2 arms). Primary endpoint: Composite primary endpoint of antiphospholipid-related adverse pregnancy outcomes. Planned start Jun 2023; status: authorised.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)Antiphospholipid antibody positivity (aPL)
Beyond the preview
Go deeper on 2023-504661-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504661-23-00.